Female genital neoplasms

PubMed Free Full Text

Ovarian cancer: treatment

Asia

• BMC Cancer
  • Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis [2023]

Austria

• Wiener klinische Wochenschrift
  • Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer [2022]

Belgium

• PLoS ONE
  • First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis [2018]

Canada

• Canadian Agency for Drugs and Technologies in Health
  • Bevacizumab for Recurrent Platinum-Sensitive Ovarian Cancer [2023]

• Current Oncology
  • Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline [2017]

• Gynecologic Oncology
  • Spatial Analysis of Adherence to Treatment Guidelines for Advanced-Stage Ovarian Cancer and the Impact of Race and Socioeconomic Status [2014]

• Ontario Health
  • Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment [2023]
  • Adjuvant Care for Stage I Ovarian Cancer [2022]
  • Systemic Therapy for Recurrent Epithelial Ovarian Cancer [2017]

Colombia

• Revista Colombiana de Obstetricia y Ginecología
  • Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer [2024]

Denmark

• Journal of Geriatric Oncology
  • Impact of surgery and chemotherapy timing on outcomes in older versus younger epithelial ovarian cancer patients: A nationwide Danish cohort study [2023]

Europe

• European Society for Medical Oncology
  • eUpdate – Newly Diagnosed Epithelial Ovarian Carcinoma Treatment Recommendations [2021]
  • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer [2020]

• European Society of Gynaecological Oncology
  • Ovarian cancer surgery [2017]
  • ESGO Advanced (stage III-IV) Ovarian Cancer Surgery Quality Indicators [2016]

France

• Annals of Surgical Oncology
  • Status of Surgical Management of Borderline Ovarian Tumors in France: are Recommendations Being Followed? Multicentric French Study by the FRANCOGYN Group [2021]

• Gynecologic Oncology
  • Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort [2022]

Germany

• Institute for Quality and Efficiency in Health Care
  • Rucaparib (ovarian cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V [2019]

• Women's Health
  • Ovarian cancer surgery in Germany: An analysis of the nationwide hospital file 2005-2015 [2022]

International

• American Journal of Therapeutics
  • Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis [2023]

• Clinical Cancer Research
  • Small Cell Carcinoma of the Ovary, Hypercalcaemic Type – genetics, new treatment targets and current management guidelines [2020]

• Cochrane Database of Systematic Reviews
  • Angiogenesis inhibitors for the treatment of epithelial ovarian cancer [2023]
  • Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer [2022]
  • Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery [2022]

• European Society of Gynaecological Oncology
  • ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors [2021]

• Gynecologic Cancer Intergroup
  • Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup [2022]
  • Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis [2021]
  • Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer [2020]
  • Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference [2017]
  • Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease [2017]
  • Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions [2017]
  • Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours [2017]
  • Survivorship as an element of clinical trials in ovarian cancer [2011]
  • 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [2005]

• International Journal of Gynecological Cancer
  • Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care [2020]

• International Journal of Hyperthermia
  • Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis [2023]

• Journal of Gynecologic Oncology
  • Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis [2022]

• Medicine
  • Reproductive and oncological outcomes of fertility-sparing surgery in patients with stage I epithelial ovarian cancer: A systematic review and meta-analysis [2022]

• World Journal of Surgical Oncology
  • Outcome quality standards in advanced ovarian cancer surgery [2020]

Italy

• Current Oncology
  • The Consistency and Quality of ChatGPT Responses Compared to Clinical Guidelines for Ovarian Cancer: A Delphi Approach [2024]

• Journal of Gynecologic Oncology
  • Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups [2022]

• Journal of Ovarian Research
  • Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status [2019]

Netherlands

• Acta Obstetricia et Gynecologica Scandinavica
  • Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study [2023]
  • Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study [2022]

• Gynecologic Oncology
  • Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study [2023]

• Gynecologic Oncology Reports
  • Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus [2022]

Republic of Korea

• ClinicoEconomics and Outcomes Research
  • Cost–utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model [2013]

• Journal of Gynecologic Oncology
  • Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines [2024]
  • Cause-specific mortality rate of ovarian cancer in the presence of competing risks of death: a nationwide population-based cohort study [2022]
  • Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement [2018]

Singapore

• Annals Academy of Medicine Singapore
  • Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer [2015]

Spain

• Clinical and Translational Oncology
  • GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012 [2013]

• Journal of Ovarian Research
  • Management of advanced ovarian cancer in Spain: an expert Delphi consensus [2021]

• Sociedad Española de Oncología Médica
  • SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023) [2024]
  • SEOM clinical guideline in ovarian cancer (2020) [2021]

• Virchows Archiv
  • Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH) [2020]

Sri Lanka

• Sri Lanka College of Obstetricians & Gynaecologists
  • Management of epithelial ovarian cancers [2021]

Sweden

• Gynecologic Oncology
  • Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer - a nationwide population-based study [2022]

United Kingdom

• British Gynaecological Cancer Society
  • British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer [2023]

• National Institute for Health and Care Excellence
  • Maximal cytoreductive surgery for advanced ovarian cancer [2023]
  • Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) [2019]
  • Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [2016]
  • Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment [2013]
  • Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer [2013]
  • Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer [2013]

• NHS England
  • Clinical commissioning policy: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults) [2023]

• Royal College of Obstetricians and Gynaecologists
  • The Use of Biomarkers to Stratify Surgical Care in Women with Ovarian Cancer [2022]
  • Targeted therapies for the management of ovarian cancer [2013]

United States

• American Society of Clinical Oncology
  • Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update [2022]
  • PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline [2020]

• Annals of Surgical Oncology
  • Is it time to centralize ovarian cancer care in the United States? [2016]

• Cancer
  • The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms [2020]

• Food and Drug Administration
  • FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRa-Positive, Platinum-Resistant Ovarian Cancer [2023]
  • FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy [2015]

• Gynecologic Oncology
  • Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients [2024]
  • Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer [2022]
  • Ovarian cancer in the United States: Contemporary patterns of care associated with improved survival [2014]

• International Journal of Gynecological Cancer
  • National trends in bowel and upper abdominal procedures in ovarian cancer surgery [2020]

• JAMA Network Open
  • Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016 [2020]

• Journal of the National Cancer Institute
  • Disparities in Ovarian Cancer Care Quality and Survival According to Race and Socioeconomic Status [2013]

• National Cancer Institute
  • State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report [2022]
  • Ovarian Germ Cell Tumors Treatment (PDQ®)
  • Ovarian Borderline Tumors Treatment (PDQ®)
  • Childhood Ovarian Cancer Treatment (PDQ®)

• National Comprehensive Cancer Network
  • NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022 [2022]
  • Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology [2021]

• Obstetrics & Gynecology
  • Trends in Relative Survival for Ovarian Cancer From 1975 to 2011 [2015]
  • Racial Disparities in the Treatment of Advanced Epithelial Ovarian Cancer [2013]

• PLoS ONE
  • Trends in extent of surgical cytoreduction for patients with ovarian cancer [2021]

• Society of Gynecologic Oncology
  • Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer - Navigating maintenance therapy for homologous recombinant proficient ovarian cancer [2022]
  • FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper [2017]
  • Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline [2016]
  • SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm [2014]
  • Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper [2014]

{Related topics}

• Topic
  • Ovarian cancer